B7-33 Peptide: RXFP1 Signaling, Relaxin Biology and Fibrosis Research
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2. It was designed to preserve selected signaling effects of relaxin while using a much simpler molecular structure than the native two-chain hormone.
Research on B7-33 has focused mainly on the relaxin family peptide receptor 1 (RXFP1), functionally selective signaling, and preclinical models of fibrosis. This guide reviews the proposed mechanism, the evidence supporting anti-fibrotic research interest, and the limitations of the current data.
What Is B7-33?
Human relaxin-2 is an insulin-like peptide hormone consisting of two peptide chains connected by disulfide bonds. B7-33 was developed as a smaller linear peptide based mainly on the relaxin B-chain. The design aimed to retain activity at RXFP1 while simplifying the molecular scaffold.
B7-33 Research at a Glance
| Area | What has been studied |
|---|---|
| Origin | Single-chain analogue derived from human relaxin-2 B-chain |
| Primary receptor | RXFP1 |
| Signaling interest | Functionally selective signaling, including ERK pathways |
| Main research area | Fibrosis and tissue-remodeling models |
| Evidence maturity | Predominantly cell and animal research |
Why RXFP1 Matters
RXFP1 is the primary receptor for relaxin-2. Activation of this G-protein-coupled receptor can influence multiple downstream signaling pathways, including cyclic AMP and ERK-related signaling.
Native relaxin produces a broad signaling profile. B7-33 was designed as a more selective agonist that may favor some downstream pathways over others, making it useful for studying how different RXFP1 signals contribute to biological effects.
What Does Functionally Selective Signaling Mean?
A receptor does not always produce one fixed output. Different ligands can stabilize different receptor states and therefore favor distinct intracellular pathways. This concept is often called biased agonism or functional selectivity.
In the original B7-33 research, the peptide was reported to activate RXFP1 while favoring ERK-associated signaling relative to strong cAMP signaling in relevant cell systems.
Anti-Fibrotic Research
Fibrosis involves excessive deposition and remodeling of extracellular matrix, particularly collagen. Preclinical studies have investigated B7-33 in several fibrosis models, including cardiac and pulmonary research.
Later studies continued to examine B7-33 in cardiovascular models and in controlled-release biomaterials designed to reduce fibrotic encapsulation around implants.
B7-33 Compared with Native Relaxin
The main scientific attraction of B7-33 is structural simplification. Native relaxin-2 is a two-chain disulfide-bonded peptide, while B7-33 is a smaller single-chain analogue.
The molecules should not be treated as interchangeable. B7-33 has a different signaling profile and does not reproduce every property of native relaxin.
Analytical Considerations
B7-33 is a defined synthetic peptide, so research quality depends on confirming that the material matches the intended sequence and has an appropriate purity profile.
HPLC can help characterize chromatographic purity and related species, while mass spectrometry can support molecular identity. See How Peptide Purity Is Tested and our peptide COA guide for more detail.
Research Limitations
- Most published findings are preclinical rather than human clinical trials.
- Different fibrosis models do not perfectly reproduce chronic human disease.
- RXFP1 signaling is cell-type dependent and can vary with receptor expression.
- Results with B7-33 should not automatically be generalized to native relaxin or other relaxin analogues.
Key Research Takeaway
B7-33 is best understood as a compact relaxin-derived research peptide developed to probe RXFP1 signaling with a simpler, functionally selective molecular scaffold. Its most prominent research area is fibrosis, where multiple preclinical studies have reported effects on tissue-remodeling endpoints.
Research Product Information
Peps In Bulk Australia lists B7-33 in 10-vial research packs. Current AUD pricing, strength, pack and available batch-documentation information is shown on the product page.
References
- Hossain MA, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Br J Pharmacol. 2018.
- Alam F, et al. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy. Biomed Pharmacother. 2023.
- Wang C, et al. Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation. 2019.
For research and educational purposes only. This article is not medical advice.
